GTx prostate-cancer drug reduces hot flashes in men
(Reuters) - Biotechnology company GTx Inc said a late-stage
trial showed its experimental drug, toremifene citrate, reduced
hot flashes in men who were on Androgen deprivation therapy
(ADT), a common treatment for advanced prostate cancer.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=2ap76E" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=2ap76E)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=KaKoxYF" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=KaKoxYF) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=ICuPZsf" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=ICuPZsf) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=2KEFtqf" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=2KEFtqf)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/244999517" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/244999517/idUKBNG33390020080303